$BIIB · BIOGEN INC.
Biogen reported Q3 FY2026 results with total revenue of $2.804B (+10.6% YoY) but swung to a GAAP net loss of $(20.6M), or $(0.14) per share, from a $466.5M profit a year ago. The loss was driven by a $283.8M surge in acquired IPR&D and upfront/milestone expense (vs $2.1M in Q3 2025) and $66.5M in restructuring charges tied to the Apellis acquisition. Product revenue grew 13.1% to $2.089B, led by newly added SYFOVRE ($191.3M) and EMPAVELI ($51.5M), while the legacy MS franchise continued to decline.
- Q3 GAAP net loss of $(20.6M) vs $466.5M profit a year ago, driven by $283.8M in acquired IPR&D and upfront/milestone expense (up from $2.1M).
- Total revenue rose 10.6% YoY to $2.804B, with product revenue up 13.1% to $2.089B, boosted by newly acquired SYFOVRE ($191.3M) and EMPAVELI ($51.5M).
- Restructuring charges surged to $66.5M in Q3 and $239.8M YTD, primarily from workforce reductions tied to the Apellis acquisition.
- SPINRAZA revenue jumped 23.2% YoY to $460.6M; SKYCLARYS grew 34.1% to $178.2M; legacy MS franchise TECFIDERA fell 51.2% to $82.0M.
- BIIB122 (LRRK2 inhibitor for Parkinson's) discontinued after Phase 2b LUMA study failed to meet primary and secondary endpoints.
Extended-hours trading shows BIIB at $250.24, down -0.98% from the regular close of $252.73, suggesting mild negative reaction to the GAAP loss and elevated expense profile. Markets closed — no regular-session reaction yet.
A $2.8B-revenue quarter producing a GAAP loss signals that Biogen's acquisition-heavy strategy is creating significant below-the-line cost pressure that investors need to track.
Biogen's pivot toward rare disease (SPINRAZA, SKYCLARYS, QALSODY) and specialized immunology (SYFOVRE, EMPAVELI) is reshaping revenue mix as legacy MS products face generic/biosimilar pressure. The Apellis acquisition adds ophthalmology and nephrology assets but brings integration costs and pipeline risk.
Restructuring charges of $239.8M YTD tied to Apellis integration signal ongoing operational disruption. Acquired IPR&D and milestone expense of $481.8M YTD (vs $249.4M prior year) reflects heavy reliance on external pipeline assets with uncertain returns. TECFIDERA generics continue to erode the legacy MS franchise.